Table 1.
Summary of tissue reactivity with reporter antibody on western blots1
| Transgene | 2.2 (6) | 1.6 (4) | 1.1 (3) | 0.3 (2) | AP1mut (2) | CREmut (5) |
| Footpad | +(5) | +(6) | -(4) | -(2) | +(4) | +(8) |
| Esophagus | +(5) | +(5) | -(3) | -(3) | +(4) | +(8) |
| Forestomach | +(5) | +(5) | -(3) | -(2) | +(4) | +(7) |
| Vagina | +(4) | +(5) | -(5) | -(4) | +(3) | +(5) |
| Tongue | +(6) | +(5) | -(4) | -(2) | +(5) | +(10) |
| Uterus (preg) | +(1) | +(1) | -(5) | -(3) | +/-(2) | +(2) |
| Bladder | -(5) | -(5) | -(4) | -(2) | -(3) | +/-(10) |
| Heart | -(4) | -(5) | -(4) | -(2) | -(4) | +/-(10) |
| Liver | T(10) | -(5) | -(4) | -(2) | -(4) | -(10) |
| Kidney | -(10) | -(5) | -(4) | -(2) | -(4) | -(7) |
1Observed immunoreactivites are reported as positive + (strong); +/- (weak), - (negative) for no detectable immunoreactivity, or T (trace) for barely detectable. These entries are followed by numbers in parentheses which indicate the number of times each tissue was assayed. Results for each line are the collective outcome of evaluation of tissue extracts derived from 2 or more founders, except for pregnant uterus (one or more). For variable staining in mutant CRE and AP1 mice, the reported result is for the majority of animals. The number of founder lines obtained for each construct is given in parentheses beside the construct name (Top line).